The global conjunctivitis market size is calculated at USD 5.56 billion in 2025 and is forecasted to reach around USD 8.66 billion by 2034, accelerating at a CAGR of 5.05% from 2025 to 2034. The North America conjunctivitis market size surpassed USD 1.90 billion in 2024 and is expanding at a CAGR of 5.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
5.1. Covid-19: Conjunctivitis Industry Impact
5.2. Conjunctivitis Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Conjunctivitis Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Conjunctivitis Market Players to deal with Covid-19 Pandemic Scenario
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increased exposure to chemicals and pollutants
6.1.1.2. Rising awareness of condition
6.1.2. Market Restraints
6.1.2.1. Lack of Self Awareness
6.1.3. Market Opportunities
6.1.3.1. Exploring specific treatment for viral conjunctivitis
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Conjunctivitis Market Revenue by Market Players
7.1.1.2. Conjunctivitis Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
8.1. Conjunctivitis Market, by Type, 2025-2034
8.1.1. Bacterial Conjunctivitis
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Viral Conjunctivitis
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Allergic Conjunctivitis
8.1.3.1. Market Revenue and Forecast (2022-2034)
9.1. Conjunctivitis Market, by Application, 2025-2034
9.1.1. Pediatric
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2022-2034)
10.1. Conjunctivitis Market, by Application, 2025-2034
10.1.1. Antibiotics
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Anti-Histaminic
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Decongestant
10.1.3.1. Market Revenue and Forecast (2022-2034)
10.1.4. Steroid Drugs
10.1.4.1. Market Revenue and Forecast (2022-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2022-2034)
11.1. North America
11.1.1. Market Revenue Forecast by Type(2022-2034)
11.1.2. Market Revenue Forecast by Patients Type (2022-2034)
11.1.3. Market Revenue Forecast by Drug Class (2022-2034)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2022-2034)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2022-2034)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2022-2034)
11.2.2. Market Revenue Forecast by Patients Type (2022-2034)
11.2.3. Market Revenue Forecast by Drug Class (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2022-2034)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2022-2034)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2022-2034)
11.3.2. Market Revenue Forecast by Patients Type (2022-2034)
11.3.3. Market Revenue Forecast by Drug Class (2022-2034)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2022-2034)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2022-2034)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2022-2034)
11.4.2. Market Revenue Forecast by Patients Type (2022-2034)
11.4.3. Market Revenue Forecast by Drug Class (2022-2034)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2022-2034)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2022-2034)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2022-2034)
11.5.2. Market Revenue Forecast by Patients Type (2022-2034)
11.5.3. Market Revenue Forecast by Drug Class (2022-2034)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2022-2034)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2022-2034)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2022-2034)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2022-2034)
12.1. Atopix Therapeutics Ltd.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Type Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Allegran
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Type Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Ocular Therapeutix, Inc.
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Type Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Santen Pharmaceutical Co. Ltd.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Type Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Novartis
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Type Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Boehringer Ingelheim
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Type Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Boehringer Ingelheim
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Type Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Sun Pharma
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Type Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Sirion Therapeutics, Inc.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Type Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Type Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client